Loading…
Pacira BioSciences, Inc. is projected to rise to $36.34 by 2027, a +43% move from its current price of $25.48. PCRX is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean strong buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/13/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 14 | $25.16 | $25.50 | $25.84 | +0.08% |
| Jul 15 | $25.04 | $25.52 | $26.01 | +0.17% |
| Jul 16 | $24.96 | $25.54 | $26.14 | +0.25% |
| Jul 17 | $24.89 | $25.56 | $26.26 | +0.33% |
| Jul 18 | $24.83 | $25.59 | $26.36 | +0.42% |
| Jul 19 | $24.78 | $25.61 | $26.46 | +0.50% |
| Jul 20 | $24.74 | $25.63 | $26.55 | +0.58% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $24.74 | $25.63 | $26.55 | +0.58% |
| Week 2 | $24.52 | $25.78 | $27.10 | +1.17% |
| Week 3 | $24.39 | $25.93 | $27.57 | +1.76% |
| Week 4 | $24.30 | $26.08 | $27.99 | +2.35% |
| Week 5 | $24.24 | $26.23 | $28.39 | +2.95% |
| Week 6 | $24.20 | $26.38 | $28.77 | +3.55% |
| Week 7 | $24.17 | $26.54 | $29.14 | +4.15% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Pacira BioSciences, Inc. is a healthcare company that engages in the development, manufacture, marketing, distribution, and sale of non-opioid pain management and regenerative health solutions to healthcare practitioners in the United States.
Its product portfolio includes EXPAREL, a bupivacaine liposome injectable suspension for postsurgical pain management; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension indicated for the management of osteoarthritis and knee pain; and iovera system, a non-opioid handheld cryoanalgesia device used to deliver controlled doses of cold temperature to targeted nerves to produce neurolytic block that interrupts the pain-transmitting signals of a peripheral nerve. It also develops PCRX-201, a novel gene therapy vector platform enabling local administration of genetic medicines with the potential to treat large prevalent diseases like osteoarthritis. It has a development and commercialization, and supply agreement with Aratana Therapeutics, Inc.
for NOCITA, a bupivacaine liposome injectable suspension product for use in animals.
The company was formerly known as Pacira Pharmaceuticals, Inc. and changed its name to Pacira BioSciences, Inc. in April 2019. Pacira BioSciences, Inc. was incorporated in 2006 and is headquartered in Brisbane, California.
PCRX is the stock of Pacira BioSciences, Inc., a healthcare company structured around non-opioid pain management and regenerative health solutions. The stock current price is $25.82 per share, with a market capitalization of $1.02B and a rank of 2560.
The company operates within the Healthcare sector. The long-range forecast points to a bullish price trajectory, with average prices rising from $25.82 in 2026 to $326.33 in 2050, and high ROI figures along the way. Sentiment shifts from Neutral in 2026 to Bullish in subsequent years, reflecting an expectation of continued upside.
A major floor 17.8% below — a decisive break under it would weaken the trend.
The nearest floor, 12.7% below — buyers have tended to step in here.
Price is pressing into resistance (1.3% away) — a breakout level to watch.
A major ceiling 10.2% above — clearing it would confirm fresh momentum.
Key PCRX support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of PCRX market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $25.58 | Sell | $25.47 | Buy |
| MA 10 | $25.40 | Buy | $25.19 | Buy |
| MA 20 | $24.27 | Buy | $24.63 | Buy |
| MA 50 | $23.75 | Buy | $23.98 | Buy |
| MA 100 | $23.49 | Buy | $23.67 | Buy |
| MA 200 | $23.38 | Buy | $23.57 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 64.11 | Neutral |
| Stoch RSI (14) | 78.90 | Neutral |
| CCI (20) | 70.60 | Neutral |
| Williams %R (14) | -10.93 | Info |
| MACD (12,26,9) | 0.13 | Buy |
| ROC (12) | 8.38 | Buy |
| Bollinger %B (20,2) | 0.75 | Neutral |
| Stochastic %K (14) | 89.07 | Sell |
| TRIX (15) | 0.30 | Buy |
| Awesome (5,34) | 1.76 | Buy |
| Ultimate (7,14,28) | 63.46 | Neutral |
| Momentum (10) | 1.11 | Buy |
| Aroon Osc (25) | 88.00 | Buy |
| Hull MA (9) | 25.64 | Sell |
| ADX (14) | 22.50 | Buy |
| ATR (14) | 0.30 | Info |
The 30-day technical picture is bullish. RSI14 is at 70, with the 50-day simple moving average at $23.73 and the 200-day simple moving average at $23.39. The nearest support is $22.25 and the nearest resistance is $25.82.
The 30-day price range spans from $23.48 to $28.39, illustrating a near-term upside potential within that band. Annualized volatility is around 30%, indicating a relatively elevated level of short-term price movement."
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $19.16 | $25.48 | $34.98 | 0% | Neutral | |
| $29.76 | $36.34 | $46.38 | +43% | Bullish | |
| $32.03 | $39.83 | $52.22 | +56% | Bullish | |
| $37.13 | $46.89 | $62.78 | +84% | Bullish | |
| $41.80 | $53.51 | $72.94 | +110% | Bullish | |
| $44.93 | $58.22 | $80.61 | +128% | Bullish | |
| $58.87 | $77.14 | $108.33 | +203% | Bullish | |
| $68.09 | $90.17 | $128.26 | +254% | Bullish | |
| $70.45 | $94.21 | $135.62 | +270% | Bullish | |
| $76.65 | $103.48 | $150.62 | +306% | Bullish | |
| $125.50 | $176.72 | $269.56 | +594% | Bullish | |
| $262.43 | $396.32 | $648.00 | +14.6x | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $19.16 | $25.48 | $30.20 | +0.00% |
| August 2026 | $22.40 | $26.21 | $31.33 | +2.87% |
| September 2026 | $23.37 | $27.49 | $33.12 | +4.86% |
| October 2026 | $23.71 | $28.00 | $33.96 | +1.88% |
| November 2026 | $23.54 | $27.89 | $34.02 | -0.39% |
| December 2026 | $24.00 | $28.53 | $34.98 | +2.29% |
Click any year to see its month-by-month PCRX forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Pacira BioSciences, Inc.'s 2026 outlook centres on $25.48, within a $19.16 to $34.98 range. That marks a 0% change versus current levels. Price action looks broadly range-bound.
By 2027, PCRX could reach as high as $46.38, with a base case around $36.34 and support toward $29.76 — roughly +43% from $25.48. Buyers look set to stay in control over this stretch.
Expect PCRX to range from $32.03 to $52.22 through 2028. The $39.83 average target implies a +56% move from current prices. That is up +10% on the projected 2027 average. Momentum favours further upside here.
The PCRX price prediction for 2029 points to an average of $46.89 (low $37.13, high $62.78) — a potential gain of +84% on today's $25.48. Buyers look set to stay in control over this stretch.
In 2030, PCRX is projected to trade between $41.80 and $72.94, averaging $53.51 — a potential gain of +110% from today's $25.48. That is up +14% on the projected 2029 average. Momentum favours further upside here.
Pacira BioSciences, Inc.'s 2031 outlook centres on $58.22, within a $44.93 to $80.61 range. That is up +9% on the projected 2030 average. That marks a +128% change versus current levels. Buyers look set to stay in control over this stretch.
By 2032, PCRX could reach as high as $108.33, with a base case around $77.14 and support toward $58.87 — roughly +203% from $25.48. Momentum favours further upside here.
Expect PCRX to range from $68.09 to $128.26 through 2033. The $90.17 average target implies a +254% move from current prices. That is up +17% on the projected 2032 average. Buyers look set to stay in control over this stretch.
The PCRX price prediction for 2034 points to an average of $94.21 (low $70.45, high $135.62) — a potential gain of +270% on today's $25.48. Momentum favours further upside here.
In 2035, PCRX is projected to trade between $76.65 and $150.62, averaging $103.48 — a potential gain of +306% from today's $25.48. That is up +10% on the projected 2034 average. Buyers look set to stay in control over this stretch.
Pacira BioSciences, Inc.'s 2040 outlook centres on $176.72, within a $125.50 to $269.56 range. That is up +71% on the projected 2035 average. That marks a +594% change versus current levels. Momentum favours further upside here.
By 2050, PCRX could reach as high as $648.00, with a base case around $396.32 and support toward $262.43 — roughly +14.6x from $25.48. Buyers look set to stay in control over this stretch.
Investing $1,000 in PCRX today (≈ 39.246468 PCRX) could be worth
$15,554.06
+$14,554.06 (+1455%) by 2050 · US Dollar
Based on the average projected PCRX price of $396.32 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in PCRXwould be worth at today's price.
$1,000 invested in PCRX on Jul 10, 2025 (≈ 42.211903 PCRX) would be worth
$1,075.56
+$75.56 (+7.6%) today · 1.08× · US Dollar
Based on a PCRX entry price of $23.69 vs. today's $25.48.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $25.39 | $1,003.54 | +0.4% |
| 1 month ago | $23.42 | $1,087.96 | +8.8% |
| 3 months ago | $23.79 | $1,071.04 | +7.1% |
| 6 months ago | $22.93 | $1,111.21 | +11.1% |
| 1 year ago | $23.69 | $1,075.56 | +7.6% |
| All time (5.0y) ago | $55.47 | $459.35 | -54.1% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our PCRX forecast.
Our base-case forecast reaches $51.00 around 2030.
Implied market cap at $51.00: $2.01B
The multi-year forecast envisions continued upside, with the average price climbing steadily across years and the ROI expanding meaningfully. In 2027 the average price is $35.91 with an ROI of 39.1% and bullish sentiment; in 2028 the average is $38.75 with an ROI of 50.1% and bullish sentiment; in 2029 the average is $44.96 with an ROI of 74.1% and bullish sentiment. By 2030 the average reaches $50.11 with an ROI of 94.1% and bullish sentiment.
Forward-looking targets continue higher: in 2040 the average is $150.81 with an ROI of 484.1% and bullish sentiment, and in 2050 the average is $326.33 with an ROI of 1163.9% and bullish sentiment.
These figures illustrate a long-run bullish trajectory, with 2030, 2040, and 2050 highlighted as key milestones for higher price levels and substantial ROI. While these are estimates and not guarantees, the trajectory emphasizes potential upside embedded in the asset’s longer-term forecast and sentiment.
Tap a question to reveal the answer.
The average forecast price in 2030 is $50.11 with an ROI of 94.1% and bullish sentiment.
Forecasts show bullish sentiment from 2027 onward, with the average price rising from $35.91 in 2027 to $326.33 in 2050 and ROI reaching 1163.9% by 2050.
Yes; the forecast shows the 2040 average at $150.81, with earlier years like 2035 at $91.93, indicating crossing $100 by 2040.
$23.48 to $28.39.
Pacira BioSciences, Inc. Community Discussion
0Share your Pacira BioSciences, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.